Tim Kutzkey, Ph.D.
The Column Group
Dr. Kutzkey joined The Column Group in 2007 and has since contributed to the conception, formation, and launch of 7 portfolio companies, including 2 seed stage investments. In addition to Cyterix, he currently serves on the board of directors for Carmot Therapeutics and Kura Therapeutics and is a board observer at Igenica. Dr. Kutzkey was formerly a scientist at KAI Pharmaceuticals, focused on cell assay and pharmacodynamic marker development for selective protein kinase C inhibitors. Prior to KAI, he worked at UC Berkeley as a graduate student and postdoctoral scholar in the lab of Dr. Robert Tjian, completing his Ph.D. in 2005. He was previously educated at Stanford University.
Lutz Giebel, Ph.D.
SV Life Sciences
Dr. Giebel is a Managing Partner based in San Francisco. Lutz currently serves on the boards of Alba, Allocure, Cyterix, Good Start Genetics, Logical Therapeutics, Lux Biosciences, Neurotech, Ophthotech, and Panoptica. Before joining SV Life Sciences in 2001 he was a Managing Partner of Didyma LLC, a biotechnology management consulting firm. Lutz was Founder, President and CEO of CyThera Inc., Founder and Chief Operating Officer of ExSAR and was Founder and Vice President of Research of MetaXen, LLC, now part of Exelixis. He joined Arris Pharmaceutical, now part of Celera, as the first biologist and subsequently held various management positions, including Senior Director of Molecular Biology. Dr Giebel received his PhD in Molecular Biology at the University of Heidelberg, Germany and did his Post Doctoral studies in Human Genetics at the University of Wisconsin, Madison.
Steven A. Everett, MBA, Ph.D.
Founder and Chief Executive Officer
Prof. Everett is a Co-Founder of Cyterix Pharmaceuticals and has served as joint CEO and CSO since the company was incorporated in April 2010. He is the inventor of the proprietary Cyterix OncoCYP™ prodrug discovery approach. Prof. Everett has 19 years experience in the discovery and pre-clinical development of prodrugs for targeted cancer therapy both in academia and the biotech industry. He retains his academic position at the University of California, San Francisco as an Adjunct Faculty member and was previously the Head of the Drug Discovery and Translational Research Group at the University of Dundee in Scotland from 2005 to 2009. He was a Principal Investigator on a Cancer Research UK-funded program of research to develop innovative prodrug strategies for the treatment of cancer. From 2008 to 2010 Prof. Everett was a consultant and a member of the scientific advisory board of Threshold Pharmaceuticals a public company with hypoxia-activated prodrugs in advanced clincial development. From 2003 to 2005 Prof. Everett served on the board of directors of Spear Therapeutics and continued to consult for the company until 2009 in prodrug discovery and translational biology. In 1992 he was recruited to the Gray Laboratory now the Gray Institute for Radiation Oncology and Biology affiliated to the University of Oxford. Over 13 years he advanced to Senior Scientist and specialized in rational ‘mechanism-led’ prodrug design focussing on the discovery and development of hypoxia-activated prodrugs for cancer treatment. Prof. Everett is a co-author of over 50 peer-reviewed scientific papers and is an inventor on 10 issued or pending patents. Prof. Everett holds a B.Sc. in chemistry and biology from the University of Ulster, a Ph.D in physical chemistry from the Hahn-Meitner Institut Berlin and an MBA with distinction from Brunel University near London.